Alvotech - Ordinary Shares (ALVO)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — Aug 17, 2026Investment Snapshot
- P/E of 45.3 — elevated valuation multiple
- Piotroski F-Score 3/9 — signs of financial weakness
- ROE of 19.6% — good return on equity
- Revenue growing at 20% annually
Alvotech - Ordinary Shares (ALVO) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $1.3 billion . Key value metrics: P/E ratio 45.3, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Alvotech - Ordinary Shares — Fundamental Analysis Summary
Alvotech - Ordinary Shares (ALVO) trades at a trailing P/E of 45.3x — 80% above the Healthcare sector average of 25.2x.
On financial health, ALVO shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and solid return on equity of 19.6% (sector average: -20.1%).
StockPik's composite Value Score for ALVO is 50/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ALVO reports a solid gross margin of 59.8% (sector average: 37.4%) and a solid operating margin of 13.3%.
ALVO shows revenue growing at 20% year-over-year, with earnings growing at 112%.